Kornimate/medical-research-clean huggingface dataset:
a phase 1/2 study of 7mw3711 in advanced solid tumors

Conditions: Advanced Solid Tumor

Summary: 7mw3711 is an antibody-drug conjugate(adc) directed to a target wildly expressed on solid tumors. this is an open-label, multicenter, phase 1/2 study to evaluate the safety, tolerability, pharmacokinetics, and efficacy of 7mw3711 in subjects with advanced solid tumors.

two parts are included in this study. the part of dose escalation and dose expansion(part 1) will enrolled subjects with advanced solid tumors and is to evaluate the safety and tolerability and to determine the maximum tolerated dose and/or the recommend phase 2 dose(rp2d) of 7mw3711 in subjects with advanced solid tumors.

Eligibility criteria:
inclusion criteria: * eastern cooperative oncology group (ecog) performance status of 0 to 1. * life expectancy of at least 3 months as assessed by the investigator. * histologically or cytologically confirmed locally advanced or metastatic solid tumor, progressive after last treatment received and who progressed on or after standard therapies or intolerant to approved therapies or who lack of effient standard therapies. * an archival tumor tissue sample(formalin-fixed paraffin-embedded (ffpe) tumor tissue block or at least 5 unstained slides) or a fresh tissue sample should be provided. if the tissue sample cannot be provided during dose escalation, enrollment into the study is allowed after discussion with the investigator * measurable or evaluable disease by recist v1.1. * have adequate hematopoietic, renal and hepatic functions. * men or women willing to use adequate contraceptive measures throughout the study. exclusion criteria: * have other prior malignancies within 3 years before the first administration. * known central nervous system metastatic disease or carcinomatous meningitis except for treated and stable brain metastases. * have significant, uncontrolled, or active cardiovascular disease. * known history of copd, or intestinal lung disease, or other respiratory diseases requring inpatient treatments within 4 weeks prior to first administration. * have adverse events due to prior antitumor therapy not resolved to grade 1 or lower by nci ctcae v5.0. * have active infections requiring treatment within 14 weeks; have infection of hiv, active infection of hcv and hbv. * prior treatment with an antibody drug conjugate (adc) that consists of an topoisomerase i inhibitor. * prior treatment with b7-h3 targeted agents. * have received chemotherapy, immunotherapy, curative radiation within 3 weeks prior to the first administration or targeted molecular within 2 weeks prior to first administration. have received chinese patent medicine or chinese herbs of anti-tumor indications within 1 weeks prior to the first administration. * have received any systemic immunosuppressants within 2 weeks prior to the first administration except for topical corticosteroids. * have received any other investigational drugs or medical device within 4 weeks prior to the first administration. * history of drug abuse including narcotic and psychiatric drugs within 12 months prior to screening. * pregnant, or nursing females.
i-smads in periodontitis

Conditions: Periodontitis; Treatment Adherence

Summary: recently, it has been stated that smads play an active role in all conditions where transforming growth factor-beta (tgf-β) is involved, including periodontal inflammation. this study aimed to examine the levels of tgf-β and inhibitor smads in saliva and gingival crevicular fluid (gcf) in patients with stage 3 grade b periodontitis before and after non-surgical periodontal treatment. twenty (20) stage 3 grade b periodontitis and 20 periodontally healthy individuals were included in the study. clinical periodontal measurements were recorded; periodontitis patients received non-surgical periodontal treatment, and gcf and saliva samples were obtained at baseline and one month after treatment. tgf-β, smad6, and smad7 were determined by elisa.


Eligibility criteria:
inclusion criteria: * have at least 20 natural teeth, excluding third molars. * periodontitis patients had at least two non-adjacent sites per quadrant with probing depth (pd) ≥ 5 mm and clinical attachment level (cal) ≥ 5 mm with gingival inflammation, and alveolar bone loss affecting \>30% of the teeth, as detected on clinical and radiographical examinations. * periodontally healthy control group had no sign of gingival inflammation, no pd \> 3mm and no evidence of attachment or bone loss exclusion criteria: * history of systemic disease. * regular use of any drugs which can effect the immune system or inflammatory response in the 6 months preceding the start of the study. * periodontal treatment during last 6 months that could affect periodontal status. * smoking. * history of radiotherapy or chemotherapy. * current pregnancy, lactation or menopause.

Keywords: smad periodontitis gingival crevicular fluid saliva
esophagoscopy in evaluating treatment in patients with stage i-iv head and neck cancer who are undergoing radiation therapy and/or chemotherapy

Conditions: Stage I Adenoid Cystic Carcinoma of the Oral Cavity; Stage I Mucoepidermoid Carcinoma of the Oral Cavity; Stage I Squamous Cell Carcinoma of the Hypopharynx; Stage I Squamous Cell Carcinoma of the Larynx; Stage I Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage I Verrucous Carcinoma of the Larynx; Stage I Verrucous Carcinoma of the Oral Cavity; Stage II Adenoid Cystic Carcinoma of the Oral Cavity; Stage II Mucoepidermoid Carcinoma of the Oral Cavity; Stage II Squamous Cell Carcinoma of the Hypopharynx; Stage II Squamous Cell Carcinoma of the Larynx; Stage II Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage II Verrucous Carcinoma of the Larynx; Stage II Verrucous Carcinoma of the Oral Cavity; Stage III Adenoid Cystic Carcinoma of the Oral Cavity; Stage III Mucoepidermoid Carcinoma of the Oral Cavity; Stage III Squamous Cell Carcinoma of the Hypopharynx; Stage III Squamous Cell Carcinoma of the Larynx; Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage III Verrucous Carcinoma of the Larynx; Stage III Verrucous Carcinoma of the Oral Cavity; Stage IV Adenoid Cystic Carcinoma of the Oral Cavity; Stage IV Mucoepidermoid Carcinoma of the Oral Cavity; Stage IV Squamous Cell Carcinoma of the Hypopharynx; Stage IV Squamous Cell Carcinoma of the Larynx; Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IV Verrucous Carcinoma of the Larynx; Stage IV Verrucous Carcinoma of the Oral Cavity

Summary: brief summary: rationale: comparing results of diagnostic procedures, such as esophagoscopy, done before and after radiation therapy and/or chemotherapy may help doctors predict a patient's response to treatment and help plan the best treatment. purpose: this clinical trial is studying esophagoscopy in evaluating treatment in patients with stage i-iv head and neck cancer who are undergoing radiation therapy and/or chemotherapy.

objectives: i. to assess the prevalence of esophageal pathology (any esophageal abnormality, specifically: esophagitis, stricture/web, infections, neoplasms) as identified by esophagoscopy in patients with hnca before and 3 months following primary radiation and/or chemotherapy. ii. to assess the changes in self-reported dysphagia symptoms as measured by the eating assessment tool. outline: patients undergo transnasal esophagoscopy at baseline and 3 months following completion of radiation therapy and/or chemotherapy.

Eligibility criteria:
inclusion * written informed consent must be obtained from all participants prior to beginning therapy; participants should have the ability to understand and be willing to sign a written informed consent document * primary diagnosis of head and neck carcinoma (oral, hypopharyngeal, laryngeal) * stage i-iv, undergoing treatment with radiation therapy +/- chemotherapy exclusion * medical history of esophageal dysfunction * pregnant women are not excluded from participation
improving self-care of behavioral variant frontotemporal dementia caregivers

Conditions: Behavioral Variant of Frontotemporal Dementia; Caregiver Stress Syndrome

Summary: the research study is being conducted to evaluate the efficacy of a virtual support intervention to reduce stress and poor self-care for caregivers of persons with behavioral variant frontotemporal degeneration (bvftd) compared to receiving health information alone.

informal caregivers of persons with frontotemporal degeneration (ftd) are an understudied population with unique needs. ftd is a common cause of young-onset dementia with no known cure. behavioral variant ftd (bvftd) is the most common of the ftd syndromes and involves a progressive disorder of emotional regulation and personality, and significant impairment in executive function. bvftd caregivers face unique challenges which are particularly stressful, including young age at which the disorder appears, behavioral symptoms like apathy and disinhibition that are severe and appear early in bvftd, and the lack of appropriate supportive services. indeed, numerous studies have demonstrated that stress, depression and burden are higher in ftd caregivers than in any of the other adrds, yet caregiver interventions tested in specifically in the ftd population have been limited to a few small studies that focus on education around patient behavior management, not caregiver self-care. the research study is being conducted to evaluate the efficacy of a virtual support intervention to reduce stress and poor self-care for caregivers of persons with behavioral variant frontotemporal degeneration (bvftd) compared to receiving health information alone. 30 caregivers will be randomized 1:1 to a health information: health information + health coaching group. catered information will be delivered via tablets over 6 months with testing dispersed at baseline, 1 month, 3 months, and 6 months.

Eligibility criteria:
inclusion criteria: * informal caregiver providing care at least 8 hours/week * reporting poor self-care on screening (health self-care neglect scale, score ≥ 2) * able to complete the protocol, e.g., adequate vision and hearing, english speaking * caregiver of a patient diagnosed bvftd exclusion criteria: * participation in another support randomized, controlled trial * untreated major psychiatric illness (use of anti-anxiety/anti-depressant medicines is acceptable and will be adjusted in analysis if group imbalance is identified.) * caregiver with cognitive impairment based on telephone interview for cognitive status (tics) score \<25
swiss 2024 continous fever monitoring in pediatric oncology patients

Conditions: Pediatric Oncology Patients With Risk for Infections

Summary: in children and adolescents undergoing chemotherapy for cancer, fever in neutropenia (fn) is the most frequent potentially lethal complication of chemotherapy for cancer. emergency hospitalization and empirical treatment with i.v. broad-spectrum antibiotics have reduced lethality from \>50% in certain high risk situations to \<1%. fever without neutropenia is a further complication requiring emergency evaluation and often emergency treatment. continuous monitoring of fever leads to earlier fever detection compared to the usual discrete fever measurements performed only for clinical reasons. earlier detection of fever leads to earlier assessment and treatment and thus can reduce the risk of complications. this study primarily aims to assess, in pediatric patients undergoing chemotherapy for cancer, the efficacy of automated fever alerts resulting from continuous fever monitoring (cfm) using a wearable device (wd), measured by the duration of intravenous antibiotics (i.v. ab) given for any cause.

primary objective the primary objective of this study is to determine if cfm fever alerts (cfm-fa) automatically sent by a wd reduce the duration of i.v. antibiotics application in children and adolescents treated with myelosuppressive chemotherapy for cancer. secondary objectives regarding safety a. number of fever episodes (fe) with safety relevant events (sres) b. number of false alerts c. number of missed alarms regarding efficacy d. delay of chemotherapy application e. duration of antimicrobial application except i.v. antibiotics f. number of fes diagnosed below or at temperature limit (tl) versus above tl g. fes according to chemotherapy intensity h. wd measured core temperature at time of fever detection by ear thermometer i. fes reported outside tars j. quality of life questionnaire k. assessment of the side-effects of the wd tertiary objective l. comparison of continuously recorded core temperature of the wd with results of discrete measurements of tympanic temperature m. pattern search using data mining

Eligibility criteria:
inclusion criteria: * chemotherapy treatment because of any malignancy expected to last ≥2 months at time of recruitment for myelosuppressive therapy, or at least 1 cycle of myeloablative chemotherapy followed by hematopoietic stem cell transplantation * age ≥1 month and \<18 years at time of recruitment * written informed consent from patients and/or parents exclusion criteria: * neonates \<1 months * local skin disease prohibiting wearing of the wd * denied written informed consent from patients and/or parents * inclusion of vulnerable participants mandatory as vital signs and fn episodes differ significantly in children and adults

Keywords: fever neutropenia pediatric oncology core temperature wearable device continous monitoring automated alerts
multi-user touch surfaces for promoting social participation and self-efficacy in upper-limb stroke rehabilitation

Conditions: Social Interaction; Self Efficacy; Stroke; Motor Activity

Summary: the purpose of this study is to compare the efficacy of conventional therapy with a framework intervention for upper limb motor rehabilitation based on the promotion of self-efficacy and social participation/interaction through a multi-user touch surface

after signing the written informed consent about participating in the study, participants will be assessed for exclusion criteria and their motor, social and depression skills prior to intervention. after this, they will undergo a 12 sessions treatment for 4 weeks in groups of three, randomly distributed for a control group and experimental group. at the end of the intervention, participants will be assessed in the same manner as before the intervention. one month after the end of the intervention, participants will be assessed for follow-up.

Eligibility criteria:
inclusion criteria: * stroke survivor exclusion criteria: * unable to write and read * hemispatial neglect * previous upper limb motor deficits/lesions that still interfere with function * history of drugs/alcohol abuse * aphasia with difficulties understanding oral communication and/or unability to express orally * token equal or under 17 * arat score lower than 10 or higher than 54 * botulinic toxin treatment in the last 4 months * beck's depression inventory higher than 31
efficacy of zinc in the treatment of pneumonia

Conditions: Pneumonia

Summary: this study is designed to evaluate the efficacy of zinc supplementation in the treatment of children under the age of two years who have been hospitalized with severe pneumonia.

this study was a randomized, double-blind, placebo-controlled clinical trial conducted between september 2003 and august 2004 at the christian medical college (cmc) hospital in vellore, india. cmc hospital is a large teaching hospital and medical center that is accessed directly by the population of vellore and adjoining districts and by referrals from local medical practitioners.

Eligibility criteria:
inclusion criteria: * children under two years old hospitalized with pneumonia exclusion criteria: * healthy children

Keywords: pneumonia zinc
cohort of cerebral cavernous malformation: multicenter prospective observational study

Conditions: Cerebral Cavernous Malformation; Intracerebral Hemorrhage

Summary: the aim of this prospective study is to reveal the natural history of symptomatic hemorrhage in adult patients with cerebral cavernous malformation with the goal of informing the treatment plan.

cerebral cavernous malformation patients with newly diagnosed, cerebral cavernous malformation who will visit one of the study centers during the period from june 2016 to december 2017. patients would be eligible for enrollment if they were 18 years of age or older and had at least 1 cerebral cavernous malformation. if the patient had multiple cavernous malformations, index cavernous malformation would be enrolled. index lesion will be determined according to the criteria. * index lesion decision criteria i. symptomatic ii. asymptomatic (priorities are as follows) 1. previous bleed 2. brain stem location 3. deep nuclei (thalamus, caudate, basal ggl, hypothalamus) 4. periventricular 5. largest all patients who would visit a study center during the enrollment period and meet these criteria will be asked to join the study. the cohort will consists of patients who agree to participate. target population of this study is 228 patients.

Eligibility criteria:
inclusion criteria: * patients with newly diagnosed cerebral cavernous malformation who agreed to participate. * 18 years old or more exclusion criteria: * patients who underwent treatment(surgery or radiosurgery) for cavernous malformation * patients who are accompanied by other serious medical problems
srs for nsclc with oligo-residual intracranial disease after first-line 3rd generation egfr-tki

Conditions: Brain Metastases; Non-small Cell Lung Cancer

Summary: despite the impressive response rate to third-generation egfr-tkis, resistance inevitably develops in most patients. stereotactic radiotherapy plays a growing role in the management of patients with brain metastasis. this study aims to evaluate the efficacy and safety of stereotactic radiotherapy for oligo-residual intracranial disease after first-line third-generation egfr inhibitors.


Eligibility criteria:
inclusion criteria: * pathologically confirmed non-small cell lung cancer; * clinical stage iv (ajcc, 8th edition, 2017); * egfr mutations: egfr l858r, egfr exon 19 deletion; * age ≥18 years; * kps score ≥70; * brain metastasis at the time of diagnosis; * complete baseline imaging assessment of metastatic lesions, including enhanced mri for brain; * receiving first-line treatment with third-generation egfr inhibitors; * after 3-6 months of third-generation egfr inhibitor treatment, imaging review indicates no progression of extracranial lesions, and brain lesions are evaluated by thin-layer (1mm layer) enhanced mri, meeting the following criteria: * no more than 10 remaining brain lesions; * the maximum diameter of the remaining brain lesions does not exceed 3cm; * at least one remaining brain lesion has a diameter greater than 5mm; * after evaluation by the researcher, all remaining brain lesions are suitable for stereotactic radiotherapy. * patient informed consent. exclusion criteria: * poor compliance with the study protocol in the investigator's opinion; * patients withdrew their informed consent and requested to withdraw from the study; * patients were unable to receive regular doses of third-generation egfr inhibitors due to other underlying conditions, viral side effects, economic factors, etc. (e.g., continuous discontinuation for more than 1 week, cumulative discontinuation for more than 2 weeks). * patients did not follow the protocol for follow-up visits as required by this study.
a cross-sectional study of female pelvic floor muscle function in chinese healthy female

Conditions: Pelvic Floor

Summary: this study aims to investigate the status of pelvic floor function of healthy female in china, including premenopausal nullipara, premenopausal women with childbirth and postmenopausal women.

this is a cross-sectional survey. the normal physical examination population is divided into three groups,including premenopausal nullipara, premenopausal women with childbirth and postmenopausal women. the pelvic floor muscle function in three groups are evaluated. the modified oxford grading scale and levator ani testing is used to quantify pfm strength through vaginal palpation. pelvic floor muscle strength ,endurance, repetition,vaginal contraction pressure and the knack test are evaluated using a phenix usb 8 neuromuscular stimulation therapy system (company: vivaltis-electronic concept lignon innovation, montpellier, france). in six different regions of china according to geographic region (northwest, southwest, north, east, northeast, and central-south china) , 1 or more hospitals in each area are selected as sub-centers, which needs to complete the evaluation of pelvic floor muscle function of 360 cases in 3 groups totally.

Eligibility criteria:
inclusion criteria: group a：premenopausal women without history of abortion or delivery 1. having sex life and tolerable to vaginal examination 2. premenopausal women without history of abortion over 16 weeks 3. premenopausal women without history of childbirth 4. planning to live locally for a long time group b：premenopausal women with childbirth 1. having sex life and tolerable to vaginal examination 2. premenopausal women with childbirth (including cesarean section or natural birth). 3. planning to live locally for a long time group c:postmenopausal women (over a year, except surgical menopause) 1. having sex life and tolerable to vaginal examination 2. postmenopausal women 3. planning to live locally for a long time exclusion criteria: 1. incontinence 4 weeks before enrollment 2. history of fecal incontinence 3. prolapse beyond the level of the hymen 4. history of radical operation of pelvic cavity(cervical cancer,rectal cancer,bladder cancer, ect） 5. history of pelvic radiotherapy 6. history of pelvic floor surgery 7. history of abortion over 16 weeks' pregnancy or in 1 year after delivery 8. duration of pregnancy 9. duration of lactation 10. history of hysterectomy 11. latex allergy 12. colpitis

Keywords: pelvic floor muscle strength premenopausal nullipara childbirth postmenopausal